Review
Open access
Oct 2026
Subcutaneous infliximab in inflammatory bowel disease: from pharmacokinetic principles to clinical practice.
INTRODUCTION Subcutaneous infliximab (CT-P13 SC) was developed to address the pronounced peak-to-trough fluctuations of intravenous dosing and the immunogenicity driven by sub-therapeutic troughs. Through a stable steady-state pharmacokinetic profile it meets the international Delphi consensus definition of a biobetter...
M. N. Quraishi, S. Elouali
· Expert Opinion on Biological... · 0 citations